Published in Hepatology on July 01, 1999
Management of varices in patients with cirrhosis. Nat Rev Gastroenterol Hepatol (2013) 0.99
Clinical pharmacology of portal hypertension. Gastroenterol Clin North Am (2010) 0.92
Evolution in the understanding of the pathophysiological basis of portal hypertension: How changes in paradigm are leading to successful new treatments. J Hepatol (2015) 0.90
Beta-blockers in liver cirrhosis. Ann Gastroenterol (2014) 0.90
Effect of propranolol on the splanchnic and peripheral renin angiotensin system in cirrhotic patients. World J Gastroenterol (2008) 0.85
After proper optimization of carvedilol dose, do different child classes of liver disease differ in terms of dose tolerance and response on a chronic basis? Saudi J Gastroenterol (2015) 0.81
Hemodynamic effects of one week of carvedilol administration on cirrhotic rats. J Gastroenterol (2006) 0.81
The effect of carvedilol and propranolol on portal hypertension in patients with cirrhosis: a meta-analysis. Patient Prefer Adherence (2015) 0.80
Contemporary concepts of the medical therapy of portal hypertension under liver cirrhosis. World J Gastroenterol (2015) 0.80
Pathophysiology of portal hypertension and its clinical links. J Clin Exp Hepatol (2011) 0.79
Carvedilol in the treatment of portal hypertension. Saudi J Gastroenterol (2011) 0.77
Recent advances in the management of variceal bleeding. Gastroenterol Rep (Oxf) (2017) 0.76
Is it time to replace propranolol with carvedilol for portal hypertension? World J Gastrointest Endosc (2015) 0.76
Primary prophylaxis of bleeding from esophageal varices in cirrhosis. J Clin Exp Hepatol (2013) 0.76
Carvedilol for portal hypertension in cirrhosis: systematic review with meta-analysis. BMJ Open (2016) 0.76
Pulmonary arterial hypertension: an unusual cause of portal hypertension. Gastroenterol Hepatol (N Y) (2012) 0.75
Hepatobiliary quiz-8 (2013). J Clin Exp Hepatol (2013) 0.75
Carvedilol--A new nonselective beta blocker. Hepatology (2000) 0.75
Hemodynamic Response to Carvedilol is Maintained for Long Periods and Leads to Better Clinical Outcome in Cirrhosis: A Prospective Study. J Clin Exp Hepatol (2016) 0.75
Novel treatment options for portal hypertension. Gastroenterol Rep (Oxf) (2017) 0.75
Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med (2000) 29.25
Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet (2006) 15.32
Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med (2001) 6.38
Relation between portal pressure response to pharmacotherapy and risk of recurrent variceal haemorrhage in patients with cirrhosis. Lancet (1995) 6.06
Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med (2000) 5.09
Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril. Circulation (2001) 3.96
Ramipril and the development of diabetes. JAMA (2001) 3.38
The treatment of portal hypertension: a meta-analytic review. Hepatology (1995) 3.11
Hemodynamic events in a prospective randomized trial of propranolol versus placebo in the prevention of a first variceal hemorrhage. Gastroenterology (1990) 2.99
Surgical resection of hepatocellular carcinoma in cirrhotic patients: prognostic value of preoperative portal pressure. Gastroenterology (1996) 2.96
Angiotensin II induces contraction and proliferation of human hepatic stellate cells. Gastroenterology (2000) 2.57
Effects of ramipril and vitamin E on atherosclerosis: the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE). Circulation (2001) 2.30
Pharmacological treatment of portal hypertension: an evidence-based approach. Semin Liver Dis (1999) 2.15
Clinical events after transjugular intrahepatic portosystemic shunt: correlation with hemodynamic findings. Gastroenterology (1998) 2.10
Zinc at glutamatergic synapses. Neuroscience (2008) 2.08
Beta-blockade with propranolol and hepatic artery blood flow in patients with cirrhosis. Hepatology (1989) 1.97
Complications of cirrhosis. I. Portal hypertension. J Hepatol (2000) 1.96
Impact of ramipril in patients with evidence of clinical or subclinical peripheral arterial disease. Eur Heart J (2004) 1.90
Propranolol in prevention of recurrent bleeding from severe portal hypertensive gastropathy in cirrhosis. Lancet (1991) 1.88
Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: effects on renal function and vasoactive systems. Hepatology (1998) 1.87
Gastric mucosal vascular ectasias causing bleeding in cirrhosis. A distinct entity associated with hypergastrinemia and low serum levels of pepsinogen I. Gastroenterology (1987) 1.77
Atrial natriuretic factor in cirrhosis with ascites: plasma levels, cardiac release and splanchnic extraction. Hepatology (1988) 1.74
Portal hypertension and variceal bleeding: an AASLD single topic symposium. Hepatology (1998) 1.74
Nitroglycerin improves the hemodynamic response to vasopressin in portal hypertension. Hepatology (1983) 1.67
Multicenter randomized controlled trial of terlipressin versus sclerotherapy in the treatment of acute variceal bleeding: the TEST study. Hepatology (2000) 1.67
Hemodynamic and humoral changes after liver transplantation in patients with cirrhosis. Hepatology (1993) 1.67
Prognostic value of early measurements of portal pressure in acute variceal bleeding. Gastroenterology (1999) 1.64
Double-blind randomized controlled trial comparing terlipressin and somatostatin for acute variceal hemorrhage. Variceal Bleeding Study Group. Gastroenterology (1996) 1.64
Desensitization to the effects of intravenous octreotide in cirrhotic patients with portal hypertension. Gastroenterology (2001) 1.62
The lung in patients with cirrhosis. J Hepatol (1990) 1.59
Increased gastric mucosal perfusion in cirrhotic patients with portal hypertensive gastropathy. Gastroenterology (1992) 1.57
Prevalence of the Cys282Tyr and His63Asp HFE gene mutations in Spanish patients with hereditary hemochromatosis and in controls. J Hepatol (1998) 1.55
Steady-state extrarenal sorbitol clearance as a measure of hepatic plasma flow. Gastroenterology (1988) 1.53
Testing non-linearity and directedness of interactions between neural groups in the macaque inferotemporal cortex. J Neurosci Methods (1999) 1.49
Propranolol plus prazosin compared with propranolol plus isosorbide-5-mononitrate in the treatment of portal hypertension. Gastroenterology (1998) 1.47
Mineralocorticoid escape in patients with compensated cirrhosis and portal hypertension. Gastroenterology (1992) 1.45
[Massive pleural effusion secondary to pancreatic-pleural fistula as first manifestation of chronic pancreatitis. Report of three cases]. Med Clin (Barc) (1997) 1.43
Limitations of laser-Doppler velocimetry and reflectance spectrophotometry in estimating gastric mucosal blood flow. Am J Physiol (1992) 1.43
Reliability of transient elastography for the diagnosis of advanced fibrosis in chronic hepatitis C. Gut (2008) 1.43
[Prospective study of community-acquired pneumonias seen in a general hospital. Diagnostic errors]. Med Clin (Barc) (1991) 1.42
Differential roles of upstream stimulatory factors 1 and 2 in the transcriptional response of liver genes to glucose. J Biol Chem (1998) 1.41
Economic outcomes analysis of stenting versus percutaneous transluminal coronary angioplasty for patients with coronary artery disease in Japan. J Invasive Cardiol (2000) 1.41
Efficacy of balloon tamponade in treatment of bleeding gastric and esophageal varices. Results in 151 consecutive episodes. Dig Dis Sci (1988) 1.40
Urate levels as a predictor of cardiac deaths: causal relation or mere association? Eur Heart J (2002) 1.40
Oral administration of clonidine in patients with alcoholic cirrhosis. Hemodynamic and liver function effects. Gastroenterology (1992) 1.40
[Recurrent oral aphthosis: treatment with pentoxifylline]. Med Clin (Barc) (1993) 1.39
[Terlipressin in the treatment of portal hypertension]. Gastroenterol Hepatol (1998) 1.39
[Severe complications of percutaneous hepatic biopsy in patients with orthotopic liver transplantation]. Gastroenterol Hepatol (1995) 1.38
[Epidemiology of head traumas. "Barcelona" data base. Objectives, design and analysis of 584 cases]. Rev Esp Anestesiol Reanim (1992) 1.38
Comparison of intravenous somatostatin and vasopressin infusions in treatment of acute variceal hemorrhage. Hepatology (1984) 1.36
Glucose-dependent liver gene expression in upstream stimulatory factor 2 -/- mice. J Biol Chem (1997) 1.34
In-vitro activity of ciprofloxacin, ceftriaxone and five other antimicrobial agents against 95 strains of Brucella melitensis. J Antimicrob Chemother (1986) 1.32
Differential expression pattern of S-adenosylmethionine synthetase isoenzymes during rat liver development. Hepatology (1996) 1.30
Renal failure after upper gastrointestinal bleeding in cirrhosis: incidence, clinical course, predictive factors, and short-term prognosis. Hepatology (2001) 1.29
Randomized comparison of long-term losartan versus propranolol in lowering portal pressure in cirrhosis. Gastroenterology (2001) 1.28
Definitions, methodology and therapeutic strategies in portal hypertension. A Consensus Development Workshop, Baveno, Lake Maggiore, Italy, April 5 and 6, 1990. J Hepatol (1992) 1.27
Antibiotic resistance of Streptococcus pneumoniae in childhood carriers. J Antimicrob Chemother (1987) 1.26
Effects of somatostatin on hepatic and systemic hemodynamics in patients with cirrhosis of the liver: comparison with vasopressin. Gastroenterology (1981) 1.25
The Study of Health Assessment and Risk in Ethnic groups (SHARE): rationale and design. The SHARE Investigators. Can J Cardiol (1998) 1.22
Pathophysiology of portal hypertension. Gastroenterol Clin North Am (1992) 1.21
Cancer antigen 125 in serum and ascitic fluid of patients with liver diseases. Clin Chem (1991) 1.20
[The quality of life in asthma: an evaluation of the AQLQ questionnaire for its use on a Spanish population. Asthma Quality of Life Questionnaire]. Arch Bronconeumol (1995) 1.18
Gas exchange and pulmonary vascular reactivity in patients with liver cirrhosis. Am Rev Respir Dis (1987) 1.17
Developing and establishing bee species as crop pollinators: the example of Osmia spp. (Hymenoptera: Megachilidae) and fruit trees. Bull Entomol Res (2002) 1.17
Bone remodelling in human immunodeficiency virus-1-infected patients. A histomorphometric study. Bone (1995) 1.17
Relevance of in vitro antimicrobial susceptibility of Brucella melitensis to relapse rate in human brucellosis. Antimicrob Agents Chemother (1986) 1.16
High survival rate of 43% in out-of-hospital cardiac arrest patients in an optimised chain of survival. Neth Heart J (2015) 1.15
Serum potassium, cardiovascular risk, and effects of an ACE inhibitor: results of the HOPE study. Clin Nephrol (2005) 1.15
Hepatic hemodynamics and the renin-angiotensin-aldosterone system in cirrhosis. Gastroenterology (1980) 1.14
Effects of F-180, a new selective vasoconstrictor peptide, compared with terlipressin and vasopressin on systemic and splanchnic hemodynamics in a rat model of portal hypertension. Hepatology (1998) 1.14
Effects of inhibiting nitric oxide biosynthesis on the systemic and splanchnic circulation of rats with portal hypertension. Br J Pharmacol (1992) 1.13
Propranolol in the prevention of the first hemorrhage from esophagogastric varices: A multicenter, randomized clinical trial. The Boston-New Haven-Barcelona Portal Hypertension Study Group. Hepatology (1991) 1.13
CD84 functions as a homophilic adhesion molecule and enhances IFN-gamma secretion: adhesion is mediated by Ig-like domain 1. J Immunol (2001) 1.13
Wedged hepatic venous pressure adequately reflects portal pressure in hepatitis C virus-related cirrhosis. Hepatology (1999) 1.12
Hemodynamic evaluation of the patient with portal hypertension. Semin Liver Dis (1986) 1.12
Family functioning and psychosocial adjustment in overweight youngsters. Int J Eat Disord (2000) 1.12
Modulation of interleukin-18 expression in human colon carcinoma: consequences for tumor immune surveillance. Int J Cancer (1999) 1.11
Design, history and results of the Thiazolidinedione Intervention with vitamin D Evaluation (TIDE) randomised controlled trial. Diabetologia (2011) 1.10
Regulation of rat liver S-adenosylmethionine synthetase during septic shock: role of nitric oxide. Hepatology (1997) 1.10
Standardised pre-hospital care of acute myocardial infarction patients: MISSION! guidelines applied in practice. Neth Heart J (2010) 1.10
Effects of propranolol on azygos venous blood flow and hepatic and systemic hemodynamics in cirrhosis. Hepatology (1985) 1.09
Superoxide dismutase gene transfer reduces portal pressure in CCl4 cirrhotic rats with portal hypertension. Gut (2008) 1.09
High incidence of porokeratosis in renal transplant recipients. Br J Dermatol (1997) 1.09